Hexavalent vaccine DTaP/IPV/Hib/HepB: PGD template
PGD template for administering hexavalent vaccine following national recommendations and the routine childhood immunisation programme.
- From:
- UK Health Security Agency
- Published
- 31 July 2017
- Last updated
-
113 June20242025 — See all updates
Applies to England
Documents
Hexavalent vaccine, DTaP/IPV/Hib/HepB: Patient Group Direction (PGD) template
Ref: UKHSA gateway number GOV-16447GOV-18480
MS Word Document, 226256 KB
This file may not be suitable for users of assistive technology.
Request an accessible format.
If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email publications@phe.gov.uk. Please tell us what format you need. It will help us if you say what assistive technology you use.
Details
This patient group direction (PGD) template supports the administration of hexavalent vaccine, DTaP/IPV/Hib/HepB, in accordance with national recommendations and the routine childhood immunisation programme.
DTaP/IPV/Hib/HepB PGD version 5.006.0 is valid from 241 July 20242025 to 241 NovemberJuly 20262028.
Practitioners must not use this PGD template until it has been authorised in Section 2. This is a legal requirement (see Human Medicines Regulations 2012). Practitioners should follow local policy/procedures to access authorised PGD documents.
This PGD template should be used with reference to current national guidance, the Green Book, and summary of product characteristics for the vaccine.
Updates to this page
Published 31 July 2017
Last updated 113 June 2024
+ show2025
href="#full-history">+ show all updates
-
Sign up for emails or print this page
Details
This patient group direction (PGD) template supports the administration of hexavalent vaccine, DTaP/IPV/Hib/HepB, in accordance with national recommendations and the routine childhood immunisation programme.
DTaP/IPV/Hib/HepB PGD version 5.006.0 is valid from 241 July 20242025 to 241 NovemberJuly 20262028.
Practitioners must not use this PGD template until it has been authorised in Section 2. This is a legal requirement (see Human Medicines Regulations 2012). Practitioners should follow local policy/procedures to access authorised PGD documents.
This PGD template should be used with reference to current national guidance, the Green Book, and summary of product characteristics for the vaccine.